On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will almost certainly by no means disappear and a vaccine will not quit it completely. He also mentioned that ministers and experts should cease ‘over-promising’ and be realistic about the prospects of a vaccine and the most likely timeline of a single, unlikely before spring subsequent year.
He then echoed his earlier warnings and these of his colleague Professor Chris Whitty that the COVID-19 fight will be a extended 1, and it will be with us for very good.
So, from this need to we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there were a single therapy that:
could cease the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in instances where patients created secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug currently proven as secure
was simple to make, scalable at the level expected to make a difference in the pandemic and was expense powerful, then would not that be anything we ought to all be getting excited about?
Certainly even though no such ‘silver bullet’ game altering therapy exists? After all, the only therapies we hear about for COVID are those which President Trump took, which had been either quite new, pricey and experimental or have a really narrow application to a certain aspect of the illness.
Properly, you heard it right here 1st – such a ‘silver bullet’ therapy does exist currently. It’s called Nylexa®, from the small UK biotech company NovaBiotics Ltd. It’s active ingredients have been safely utilized in medicines that treat unrelated situations for more than 30 years.
https://www.medcare.org/ found Nylexa’s prospective added benefits in COVID-19 following a decade of investigation in tricky to treat, drug-resistant infections, such as the complicated chest infections and inflammation associated with cystic fibrosis (CF) lung illness. In March they applied for a £1m grant from Innovate UK (representing the government) to start off clinical research. That grant was sooner or later awarded earlier this month, and the government are now taking into consideration no matter whether or not to incorporate Nylexa on two separate NHS platform research.
But why, I hear you ask, if this is so very good have we not heard about it prior to? Why are the government and the press not shouting about this from the rooftops? Why is this not getting demanded by clinicians desperate for efficient therapies for their individuals?
I am afraid to say, it all boils down to income. Tiny biotech companies uncover it difficult to get focus as they do not have the sources out there to their bigger greater funded rivals. The names we study about consistently when it comes to ground breaking new therapies are invariably massive multi-national pharmaceutical corporations with deep pockets and significant budgets to promote their own particular wares. They make certain their drugs get the essential focus. NovaBiotics is a smaller private company funded by a group of loyal and supportive shareholders so however don’t have the resources to compete for interest with the huge boys.
Which is why this scenario is so frustrating. In mitigating the health consequences of contracting COVID-19, Nylexa® could increase public self-assurance of living with the virus for the longer term and potentially enable a higher degree of normality to return to the way in which we live, benefiting the economy directly in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. But having people today in positions of influence to take notice amongst all the other people competing for their consideration is really challenging indeed.
It is reported that there are thousands of possible COVID-19 treatments in clinical trials across the planet. I would challenge any person to show me one particular which has the same possible for optimistic impact as Nylexa®, yet this is not presently element of any trial, in spite of its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials right away. The sooner it gets tested, the sooner it can be employed to assistance sort out the mess the pandemic has triggered to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology corporation focused on the design and style and improvement of initially-in-class therapies for difficult-to-treat, medically unmet infectiousdiseases triggered by bacteria and fungi and respiratory conditions like cystic fibrosis and COVID-19.
A top innovator in the anti-infectives space, the Company’s robust technology and enterprise model has been validated through profitable improvement, from notion to late stage clinical improvement, of its most advanced item candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, higher-value drug candidates including NP339 (Division of Health and Social Care funded programme) for life threatening, drug resistant invasive fungal illness and NP432 for multi- drug resistant bacterial infections.